Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Post by Shockeron Nov 02, 2022 7:16pm
170 Views
Post# 35068213

Biorun should we not sell?

Biorun should we not sell?

I cant complain I took a chance with a company thats on the venture and an agreement with Wuxi to produce non disclosed amount  of 1067 to date. A major deal in China, someone who was an expert in closing deals , A retired Bayer science expert, IC, PRc or Pr and lets not forget Biorun. 

Package it together you get 11.5 cents Not to say this can jump the first 1/2 in 2023, 2024 or was that 2025. I wonder what if you take all the salaries of Sirona what number comes up.. 

But I the shareholder will take it on the chin. I think all of Sirona team worked hard to date they just cant pass the finish line. Sometimes  you can have everything go your way, But bad news is something find hard to disclose at times to  shareholders. I amd not sure why the AGM was not the 24th. 

As I said dont blame Sirona, just poor communication that should be communicated out to us the investor regardless of good or bad  but at least we could understand even if that means 5 cents or 1 buck.....



<< Previous
Bullboard Posts
Next >>